EA036942B1 - Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза - Google Patents

Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза Download PDF

Info

Publication number
EA036942B1
EA036942B1 EA201690980A EA201690980A EA036942B1 EA 036942 B1 EA036942 B1 EA 036942B1 EA 201690980 A EA201690980 A EA 201690980A EA 201690980 A EA201690980 A EA 201690980A EA 036942 B1 EA036942 B1 EA 036942B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chlorophenyl
compound
compounds
treatment
present
Prior art date
Application number
EA201690980A
Other languages
English (en)
Russian (ru)
Other versions
EA201690980A1 (ru
Inventor
Шон Кэнпил
Джуд Кэнон
Пол Хьюз
Джонатан Д. Олинер
Ричард Дж. Риклес
Анн Й. Саики
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201690980A1 publication Critical patent/EA201690980A1/ru
Publication of EA036942B1 publication Critical patent/EA036942B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EA201690980A 2013-11-11 2014-11-11 Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза EA036942B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902717P 2013-11-11 2013-11-11
PCT/US2014/065034 WO2015070224A2 (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Publications (2)

Publication Number Publication Date
EA201690980A1 EA201690980A1 (ru) 2016-09-30
EA036942B1 true EA036942B1 (ru) 2021-01-18

Family

ID=52001089

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690980A EA036942B1 (ru) 2013-11-11 2014-11-11 Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
EA202092456A EA202092456A3 (ru) 2013-11-11 2014-11-11 Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092456A EA202092456A3 (ru) 2013-11-11 2014-11-11 Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака

Country Status (33)

Country Link
US (3) US20160287569A1 (enExample)
EP (2) EP3068393B9 (enExample)
JP (5) JP2016535795A (enExample)
KR (3) KR102473485B1 (enExample)
CN (2) CN105934255A (enExample)
AP (1) AP2016009243A0 (enExample)
AU (3) AU2014346354A1 (enExample)
BR (1) BR112016010564A2 (enExample)
CA (1) CA2930244A1 (enExample)
CL (1) CL2016001131A1 (enExample)
CY (1) CY1125358T1 (enExample)
DK (1) DK3068393T5 (enExample)
EA (2) EA036942B1 (enExample)
ES (1) ES2916721T3 (enExample)
HR (1) HRP20220718T1 (enExample)
HU (1) HUE059351T2 (enExample)
IL (2) IL245568B (enExample)
LT (1) LT3068393T (enExample)
MA (1) MA39094B1 (enExample)
MX (6) MX2020013670A (enExample)
MY (1) MY192088A (enExample)
NZ (2) NZ758548A (enExample)
PH (1) PH12016500871A1 (enExample)
PL (1) PL3068393T3 (enExample)
PT (1) PT3068393T (enExample)
RS (1) RS63348B9 (enExample)
SG (1) SG10201902429PA (enExample)
SI (1) SI3068393T1 (enExample)
SM (1) SMT202200241T1 (enExample)
TN (1) TN2016000176A1 (enExample)
UA (1) UA120750C2 (enExample)
WO (1) WO2015070224A2 (enExample)
ZA (1) ZA201603342B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
JP6342808B2 (ja) 2011-10-18 2018-06-13 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
SMT202200241T1 (it) * 2013-11-11 2022-09-14 Amgen Inc Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri
EP3197477A4 (en) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016133194A1 (ja) 2015-02-20 2016-08-25 第一三共株式会社 がんの併用治療法
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108348611A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 使用pi3k抑制剂和mdm2抑制剂的联合疗法
EP3340989B1 (en) * 2015-08-28 2023-08-16 Novartis AG Mdm2 inhibitors and combinations thereof
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN109843329A (zh) * 2016-10-17 2019-06-04 第一三共株式会社 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL308399B2 (en) 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
MX2020012503A (es) * 2018-05-25 2021-08-11 Kartos Therapeutics Inc Métodos de tratamiento de neoplasias mieloproliferativas.
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
AR116904A1 (es) * 2018-12-11 2021-06-23 Kartos Therapeutics Inc Métodos y composiciones para el tratamiento de un trastorno oftálmico
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
AU2020323033A1 (en) 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
US20230218575A1 (en) * 2020-06-15 2023-07-13 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeautic applications thereof
WO2022036067A1 (en) * 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Combination therapies for use in treating cancer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024254156A1 (en) * 2023-06-05 2024-12-12 Kartos Therapeutics, Inc. Treatment of endometrial cancer with mdm2 inhibitors
WO2025098488A1 (zh) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319378A1 (en) * 2010-06-04 2011-12-29 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12333A (en) 2000-07-19 2004-04-06 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
EP1809282B1 (en) 2004-10-18 2013-01-09 Amgen, Inc Thiadiazole compounds and methods of use
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
HUE028954T2 (en) 2007-03-23 2017-01-30 Amgen Inc Heterocyclic compounds and their use
PT2139882E (pt) 2007-03-23 2014-01-30 Amgen Inc Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k)
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
CA2689092C (en) 2007-06-07 2013-01-15 Amgen Inc. Raf kinase modulators and methods of use
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2694136C (en) 2007-08-02 2013-09-17 Amgen Inc. Pi3 kinase modulators and methods of use
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
EP2387570A1 (en) 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
MX2011008674A (es) 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2010132598A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
MX2011013901A (es) 2009-06-25 2012-05-08 Amgen Inc Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
EP2445900B1 (en) 2009-06-25 2016-03-02 Amgen, Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
NZ598758A (en) 2009-09-11 2013-12-20 Amgen Inc N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
KR20120031734A (ko) * 2010-09-27 2012-04-04 삼성전자주식회사 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
MX2013006020A (es) * 2011-01-31 2013-10-01 Celgene Corp Composicion farmaceutica de analogos de citidina y metodos para su uso.
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013144923A1 (en) 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
JP6417338B2 (ja) 2013-02-19 2018-11-07 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物
JP6266659B2 (ja) 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US20150031642A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
SMT202200241T1 (it) * 2013-11-11 2022-09-14 Amgen Inc Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319378A1 (en) * 2010-06-04 2011-12-29 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
BOSE P, GRANT S: "Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)", LEUKEMIA RESEARCH REPORTS, ELSEVIER LTD., GB, vol. 2, no. 1, 1 January 2013 (2013-01-01), GB, pages 12 - 14, XP002740451, ISSN: 2213-0489, DOI: 10.1016/j.lrr.2012.11.006 *
CHITHRA D. PALANI; JAMES F. BECK; JÜRGEN SONNEMANN: "Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 1, 3 August 2010 (2010-08-03), Bo, pages 25 - 36, XP035000732, ISSN: 1573-0646, DOI: 10.1007/s10637-010-9510-7 *
FALCHOOK G S, LEWIS K D, INFANTE J R, GORDON M S, VOGELZANG N J, DEMARINI D J, SUN P, MOY C, SZABO S A, ROADCAP L T, PEDDAREDDIGAR: "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 8, 1 August 2012 (2012-08-01), AMSTERDAM, NL, pages 782 - 789, XP002727794, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(12)70269-3 *
FENG J, TAMASKOVIC R, YANG Z, BRAZIL D P, MERLO A, HESS D, HEMMINGS B A: "Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 279, no. 34, 20 August 2004 (2004-08-20), pages 35510 - 35517, XP002740653, ISSN: 0021-9258, DOI: 10.1074/jbc.M404936200 *
FLAHERTY KEITH T, ET AL: "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 367, no. 18, 1 November 2012 (2012-11-01), US, pages 1694 - 1703, XP002725869, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1210093 *
GILES FRANCIS; CORTES JORGE; BERGSTROM DONALD A; XIAO ALAN; BRISTOW PENNY; JONES DAN; VERSTOVSEK SRDAN; THOMAS DEBORAH; KANTARJIAN: "MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), US, pages 52a, XP009124755, ISSN: 0006-4971 *
J. G. GREGER, S. D. EASTMAN, V. ZHANG, M. R. BLEAM, A. M. HUGHES, K. N. SMITHEMAN, S. H. DICKERSON, S. G. LAQUERRE, L. LIU, T. M. : "Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC., vol. 11, no. 4, 1 April 2012 (2012-04-01), pages 909 - 920, XP055057160, ISSN: 15357163, DOI: 10.1158/1535-7163.MCT-11-0989 *
J. M. GOZGIT, WONG M. J., WARDWELL S., TYNER J. W., LORIAUX M. M., MOHEMMAD Q. K., NARASIMHAN N. I., SHAKESPEARE W. C., WANG F., D: "Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC., vol. 10, no. 6, 1 June 2011 (2011-06-01), pages 1028 - 1035, XP055056925, ISSN: 15357163, DOI: 10.1158/1535-7163.MCT-10-1044 *
JI Z, KUMAR R, TAYLOR M, RAJADURAI A, MARZUKA-ALCALÁ A, CHEN Y E, NJAUW C N, FLAHERTY K, JÖNSSON G, TSAO H.: "Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 16, 15 August 2013 (2013-08-15), US, pages 4383 - 4391, XP002734225, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0074 *
JI Z, NJAUW C N, TAYLOR M, NEEL V, FLAHERTY K T, TSAO H: "p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, US, vol. 132, no. 2, 1 February 2012 (2012-02-01), US, pages 356 - 364, XP002694638, ISSN: 1523-1747, DOI: 10.1038/jid.2011.313. *
KAO C L, HSU H S, CHEN H W, CHENG T H: "Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.", CANCER LETTERS, NEW YORK, NY, US, vol. 286, no. 2, 28 December 2009 (2009-12-28), US, pages 250 - 259, XP002740446, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2009.05.031 *
KENSUKE KOJIMA, KONOPLEVA MARINA, MCQUEEN TERESA, BRIEN SUSAN O ', PLUNKETT WILLIAM, ANDREEFF MICHAEL: "Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription- dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia", BLOOD, vol. 108, no. 3, 1 August 2006 (2006-08-01), pages 993 - 1000, XP055140017, DOI: 10.1182/blood-2005-12-5148 *
KHOURY H J, CORTES J E, KANTARJIAN H M, GAMBACORTI-PASSERINI C, BACCARANI M, KIM D W, ZARITSKEY A, COUNTOURIOTIS A, BESSON N, LEIP: "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, vol. 119, no. 15, 12 April 2012 (2012-04-12), US, pages 3403 - 3412, XP002740449, ISSN: 1528-0020, DOI: 10.1182/blood-2011-11-390120 *
KOJIMA K, KONOPLEVA M, SAMUDIO I J, RUVOLO V, ANDREEFF M.: "Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 67, no. 7, 1 April 2007 (2007-04-01), US, pages 3210 - 3219, XP002740444, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-2712 *
KOJIMA K, KONOPLEVA M, SAMUDIO I J, SCHOBER W D, BORNMANN W G, ANDREEFF M.: "Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.", CELL CYCLE, LANDES BIOSCIENCE, US, vol. 5, no. 23, 1 December 2006 (2006-12-01), US, pages 2778 - 2786, XP002740450, ISSN: 1551-4005, DOI: 10.4161/cc.5.23.3520 *
LIU D, XING M.: "Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.", THYROID., MARY ANN LIEBERT, NEW YORK, NY., US, vol. 18, no. 8, 1 August 2008 (2008-08-01), US, pages 853 - 864, XP002740459, ISSN: 1050-7256, DOI: 10.1089/thy.2007.0357 *
LONG J, PARKIN B, OUILLETTE P, BIXBY D, SHEDDEN K, ERBA H, WANG S, MALEK S N: "Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, vol. 116, no. 1, 8 July 2010 (2010-07-08), US, pages 71 - 80, XP002740447, ISSN: 1528-0020, DOI: 10.1182/blood-2010-01-261628 *
LU WENGE ET AL: "Activation of p53 by roscovitine-mediated suppression of MDM2 expression", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 20, no. 25, 31 May 2001 (2001-05-31), London, pages 3206 - 3216, XP002292792, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1204412 *
MARTINELLI E, TROIANI T, D'AIUTO E, MORGILLO F, VITAGLIANO D, CAPASSO A, COSTANTINO S, CIUFFREDA L P, MEROLLA F, VECCHIONE L, DE V: "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 133, no. 9, 1 November 2013 (2013-11-01), US, pages 2089 - 2101, XP002740445, ISSN: 0020-7136, DOI: 10.1002/ijc.28236 *
NAGMA KHAN, MICHAEL JEFFERS, SAMPATH KUMAR, CRAIG HACKETT, FERENC BOLDOG, NICHOLAI KHRAMTSOV, XIAOZHONG QIAN, EVAN MILLS, STANNY�C: "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY., vol. 409, no. 2, 15 January 2008 (2008-01-15), pages 581, XP055074060, ISSN: 02646021, DOI: 10.1042/BJ20070779 *
TIANJUN ZHOU, COMMODORE LOIS, HUANG WEI-SHENG, WANG YIHAN, THOMAS MATHEW, KEATS JEFF, XU QIHONG, RIVERA VICTOR M., SHAKESPEARE WIL: "Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance", CHEMICAL BIOLOGY & DRUG DESIGN, BLACKWELL MUNKSGAARD, vol. 77, no. 1, 1 January 2011 (2011-01-01), pages 1 - 11, XP055065379, ISSN: 17470277, DOI: 10.1111/j.1747-0285.2010.01054.x *
WANG, D. BOERNER, S.A. WINKLER, J.D. LORUSSO, P.M.: "Clinical experience of MEK inhibitors in cancer therapy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, vol. 1773, no. 8, 1 August 2007 (2007-08-01), NL, pages 1248 - 1255, XP022181677, ISSN: 0167-4889, DOI: 10.1016/j.bbamcr.2006.11.009 *
WEIGUO ZHANG, MARINA KONOPLEVA, JARED K. BURKS, KAREN C. DYWER, WENDY D. SCHOBER, JER-YEN YANG, TERESA J. MCQUEEN, MIEN-CHIE HU: "Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 6, 15 March 2010 (2010-03-15), US, pages 2424 - 2434, XP002740443, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-09-0878 *
ZAULI G, VOLTAN R, BOSCO R, MELLONI E, MARMIROLI S, RIGOLIN G M, CUNEO A, SECCHIERO P.: "Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 4, 15 February 2011 (2011-02-15), US, pages 762 - 770, XP002740448, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2572 *

Also Published As

Publication number Publication date
MX2022012320A (es) 2022-10-27
MX2020001550A (es) 2022-04-26
US20220280495A1 (en) 2022-09-08
US20160287569A1 (en) 2016-10-06
EP3068393A2 (en) 2016-09-21
KR102305351B1 (ko) 2021-09-24
HUE059351T2 (hu) 2022-11-28
WO2015070224A3 (en) 2015-08-13
WO2015070224A2 (en) 2015-05-14
CL2016001131A1 (es) 2017-04-17
MX378969B (es) 2025-03-11
CA2930244A1 (en) 2015-05-14
JP2019142916A (ja) 2019-08-29
JP2022009805A (ja) 2022-01-14
MX2022008175A (es) 2022-08-15
SMT202200241T1 (it) 2022-09-14
AU2020201321B2 (en) 2022-03-10
EP3068393B1 (en) 2022-03-09
PH12016500871A1 (en) 2016-07-04
EA202092456A3 (ru) 2021-09-30
SI3068393T1 (sl) 2022-11-30
AU2014346354A1 (en) 2016-05-26
AU2020201321A1 (en) 2020-03-12
RS63348B9 (sr) 2022-10-31
JP2016535795A (ja) 2016-11-17
TN2016000176A1 (en) 2017-10-06
EP4039256A1 (en) 2022-08-10
HRP20220718T1 (hr) 2022-09-30
BR112016010564A2 (pt) 2017-10-10
MA39094A1 (fr) 2018-07-31
SG10201902429PA (en) 2019-04-29
LT3068393T (lt) 2022-08-10
DK3068393T5 (da) 2022-08-22
IL245568B (en) 2021-09-30
EP3068393B9 (en) 2022-07-20
MX2019009853A (es) 2019-10-14
MX391859B (es) 2025-03-12
JP2023033414A (ja) 2023-03-10
JP2021004259A (ja) 2021-01-14
KR102473485B1 (ko) 2022-12-01
NZ720766A (en) 2022-02-25
EA202092456A2 (ru) 2021-05-31
DK3068393T3 (da) 2022-06-13
RS63348B1 (sr) 2022-07-29
EA201690980A1 (ru) 2016-09-30
KR20210119550A (ko) 2021-10-05
AP2016009243A0 (en) 2016-05-31
MA39094B1 (fr) 2020-06-30
MX2020013670A (es) 2022-09-30
AU2022201495A1 (en) 2022-03-24
US10881648B2 (en) 2021-01-05
US20190290630A1 (en) 2019-09-26
KR20220167335A (ko) 2022-12-20
ZA201603342B (en) 2025-04-30
UA120750C2 (uk) 2020-02-10
CY1125358T1 (el) 2024-09-20
CN105934255A (zh) 2016-09-07
MX393610B (es) 2025-03-24
JP6972274B2 (ja) 2021-11-24
PT3068393T (pt) 2022-06-14
MX2016006025A (es) 2016-12-02
NZ758548A (en) 2022-02-25
MY192088A (en) 2022-07-26
CN112933236A (zh) 2021-06-11
IL245568A0 (en) 2016-06-30
ES2916721T3 (es) 2022-07-05
KR20160074012A (ko) 2016-06-27
IL285646A (en) 2021-09-30
PL3068393T3 (pl) 2022-10-03

Similar Documents

Publication Publication Date Title
EA036942B1 (ru) Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
EP2694485B1 (en) Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments
JP2023065588A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
US12295939B2 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
JP2022544211A (ja) がんの治療における使用のための重水素化化合物
TW201028393A (en) Kinase inhibitors and methods of their use
KR20160018576A (ko) Mdm2 저해제의 결정형 및 그의 제조 방법
US20230054028A1 (en) Pd-l1 antagonist compound
HK40078013A (en) Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
EP4495111A1 (en) Novel compound and use thereof for inhibiting checkpoint kinase 2
HK40058270A (en) Pd-l1 antagonist compound
HK1228256B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1228256A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1193753A (en) Combinations of akt inhibitor compounds and erlotinib, and methods of use